Metuxtan (metformin): Reviews and patient testimonials

Metuxtan SR 500 mg prolonged release tablets

• Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:

- at high risk for developing overt type 2 diabetes mellitus and

- still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months

Treatment with Metuxtan SR prolonged release tablet must be based on a risk score incorporating appropriate measures of glycaemic control and including evidence of high cardiovascular risk.

Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.

*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose

Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.

Metuxtan SR prolonged release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.